Tirzepatide carries two FDA-approved indications today, type 2 diabetes and chronic weight management, and the same molecule is sold under two different brand names depending on which one a prescriber is treating. A third indication, moderate to severe obstructive sleep apnea in adults with obesity, has since been added, while heart failure, fatty liver disease, and kidney disease remain investigational and unapproved. The split between an approved indication and a studied use is the line that decides what the published record can claim with human clinical evidence behind it.
| Use | Regulatory status | Patient population |
|---|---|---|
| Type 2 diabetes | FDA-approved | Adults, adjunct to diet and exercise |
| Chronic weight management | FDA-approved | Adults with obesity or overweight plus a comorbidity |
| Obstructive sleep apnea | FDA-approved | Adults with moderate to severe OSA and obesity |
| Heart failure, fatty liver, kidney disease | Investigational, not approved | Under study in clinical trials |
Tirzepatide holds three FDA-approved indications, type 2 diabetes, chronic weight management, and moderate to severe obstructive sleep apnea in adults with obesity, while heart failure, fatty liver disease, and chronic kidney disease remain investigational.
The type 2 diabetes indication is the original one, and the labeled record frames the drug as an adjunct to diet and exercise rather than a replacement for them. The approval is specific to type 2 diabetes in adults; it does not extend to type 1, where the underlying biology differs and safety and effectiveness have not been shown.
Tirzepatide is FDA-approved for type 2 diabetes in adults under the brand name Mounjaro, indicated as an adjunct to diet and exercise to improve glycemic control, and is not approved for type 1 diabetes.
The weight-management approval is a separate product from the diabetes version, and the labeled population turns on body mass index plus, for the lower threshold, a qualifying weight-related condition. The obesity trial program reported average loss of roughly 20 percent or more of starting body weight at the higher doses, a magnitude that exceeded most earlier weight medications, and the indication is written for chronic ongoing use because weight tends to return when the drug is stopped.
Tirzepatide is FDA-approved for chronic weight management under the brand name Zepbound in adults with a BMI of 30 or greater, or 27 or greater with at least one weight-related condition, with higher doses producing average loss of roughly 20 percent of body weight in trials.
The published record treats the two brands as a deliberate separation, not a marketing flourish: each indication required its own clinical trial program and its own regulatory submission, so the resulting approvals were packaged as distinct products. The separation does real work at the point of care and at the point of payment, since diabetes and obesity drugs frequently sit under different formulary rules, with weight-loss medications often facing tighter coverage or outright exclusion that does not apply to diabetes therapies.
Tirzepatide is sold as Mounjaro for type 2 diabetes and Zepbound for weight management because each indication required its own clinical trial program and regulatory submission, and the separate brands keep the products distinct for prescribers, pharmacies, and payers.
Qualifying criteria differ by indication but share a set of absolute contraindications that disqualify a patient regardless of which condition is being treated. The diabetes indication turns on a type 2 diagnosis in an adult; the weight-management indication turns on body mass index with or without a comorbidity, and both are restricted to adults because pediatric use has not been established.
Both approved indications are restricted to adults and carry absolute contraindications for a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2, alongside indication-specific criteria based on type 2 diabetes diagnosis or body mass index.
Several conditions sit in the research pipeline without yet being approved indications, and the distinction is legally load-bearing: until a regulator reviews the trial evidence and adds an indication to the label, the use is investigational and the manufacturer cannot market the drug for it. Moving from promising trial data to a formal approval commonly takes several years, since it requires completing large outcome studies, submitting the data, and waiting through the agency's evaluation.
Tirzepatide is under investigation for heart failure with preserved ejection fraction, metabolic dysfunction-associated steatohepatitis, and chronic kidney disease, but none of these is an approved indication, so use for them remains investigational.
Approval is granted country by country or region by region, so tirzepatide's status is not uniform worldwide. In the United States the Food and Drug Administration cleared the diabetes use first and later the weight-management and sleep apnea uses, while the European Medicines Agency conducts its own independent review on its own schedule, which means an indication can be approved in one region while still pending in another.
| Authority | Scope | Review behavior |
|---|---|---|
| FDA (United States) | Per-indication approval | Cleared diabetes first, then weight management and OSA |
| EMA (Europe) | Marketing authorization across member states | Independent scientific review on a separate schedule |
| Other national authorities | Country-specific | Own queues, evidence requirements, and filing timelines |
Regulatory approval for tirzepatide is granted separately by each authority, so the Food and Drug Administration, the European Medicines Agency, and other national regulators may approve indications on different schedules and with differently worded labels.
Off-label prescribing is legal and common in medicine, and the published record places the responsibility for an off-label choice squarely on the licensed prescriber rather than the manufacturer. The manufacturer is not permitted to market the drug for any use outside its approved indications, so off-label use spreads through clinical experience and published research rather than advertising, and it commonly affects payment because insurers frequently decline to cover a drug used outside its labeled indications.
Off-label prescribing of tirzepatide is legal at a licensed prescriber's discretion, but the manufacturer cannot market the drug outside its approved indications, the prescriber bears legal and professional responsibility for the choice, and insurers frequently decline to cover off-label use.
Educational use only. This article describes what the published scientific and clinical literature reports about Tirzepatide. It is not medical advice, and it does not recommend, prescribe, or tell anyone to use anything described here. The regulatory status shown at the top of this page reflects what the record showed on the date given there and can change. mdpep.com does not sell any substance described here, does not endorse human use of it, and does not direct anyone to obtain it.
Talk to a licensed prescriber. Whether a treatment described here is appropriate for you depends on your medical history, your current medications, and the monitoring you may need. A licensed healthcare provider can evaluate your situation.
This is not guidance for your situation. Nothing here accounts for your medical history, your current medications, or anything else specific to you, and none of it should be used to make a decision about your own health.
Affiliate disclosure. Some links on this site are affiliate links, and mdpep.com may earn a commission when they are used. That never affects what is written here, it is not an endorsement of any vendor, and it is not a statement that anything described on this page is available to buy.
Every claim here ties to a named primary source and a date, written as plain documentation with nothing for sale. That is how MD PEP covers the whole peptide market.
